Clinical Benefits of Baricitinib Therapy According to Scalp Hair Regrowth in Patients with Severe Alopecia Areata

作者：Maryanne M. Senna, Ohsang Kwon, Bianca Maria Piraccini, Rodney Sinclair, Susan Ball, Yuxin Ding, Yun-Fei Chen, Yves Dutronc, Brett King · 发表于：Dermatology and Therapy · 年份：2023 · DOI：10.1007/s13555-023-01063-2 · 被引用次数：7 · 研究领域：Hair Growth and Disorders、Facial Rejuvenation and Surgery Techniques、Dyeing and Modifying Textile Fibers

The present analyses report integrated results from BRAVE-AA1 (NCT03570749) and BRAVE-AA2 (NCT03899259) on the clinical benefits of baricitinib treatment on the basis of the amount of scalp hair regrowth through 52 weeks of treatment. This post hoc analysis was conducted with data from patients who were treated continuously for 52 weeks with baricitinib 4 mg or 2 mg. Clinical outcomes were assessed using the Severity of Alopecia Tool (SALT) and Clinician-Reported Outcome (ClinRO) for Eyebrow (EB) and Eyelash (EL) hair. Secondary measures included the Hospital Anxiety and Depression Scale and Skindex-16 adapted for alopecia areata. At week 52, patients were classified into three subgroups: SALT ≤ 20 response, intermediate response (achieved a 30% improvement from baseline (SALT 30 ) without a SALT score ≤ 20), or nonresponse (never achieved SALT 30 ). The criterion of SALT 30 approximates a minimal clinical meaningful response to therapy. At week 52, with baricitinib 4 mg treatment, the greatest (70%) improvement in EB and EL was observed in responders, but approximately 50% of patients with intermediate response and 20% of nonresponders experienced complete/nearly complete EB and EL regrowth. Improvement in emotional distress was directionally related to improvements in scalp hair regrowth, while impact on quality of life was proportionately greater for the responder subgroup. Clinically meaningful regrowth in eyebrow and eyelash hair can occur in the absence of complete scal...